Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACHLNASDAQ:ASRTNASDAQ:LPTXNASDAQ:PYRGF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHLAchilles Therapeutics$1.48$1.47$0.63▼$1.51$60.83M1.25589,810 shsN/AASRTAssertio$0.61-1.1%$0.66$0.51▼$1.80$58.30M0.32688,260 shs606,190 shsLPTXLeap Therapeutics$0.40+6.6%$0.37$0.22▼$4.79$16.58M-0.17831,188 shs613,676 shsPYRGFPyroGenesis Canada$0.33-0.4%$0.35$0.30▼$0.80$61.63M0.7911,330 shs103 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHLAchilles Therapeutics0.00%0.00%0.00%+7.25%+66.33%ASRTAssertio-1.09%-0.21%-1.82%-29.43%-42.03%LPTXLeap Therapeutics+6.64%+18.69%+23.46%-20.73%-85.87%PYRGFPyroGenesis Canada-0.36%+1.38%+6.48%-14.26%-26.38%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACHLAchilles TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AASRTAssertio2.0576 of 5 stars3.51.00.00.02.40.81.3LPTXLeap Therapeutics2.503 of 5 stars3.14.00.00.02.90.01.3PYRGFPyroGenesis CanadaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACHLAchilles Therapeutics 0.00N/AN/AN/AASRTAssertio 3.00Buy$2.75351.78% UpsideLPTXLeap Therapeutics 2.25Hold$4.921,129.17% UpsidePYRGFPyroGenesis Canada 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest LPTX, PYRGF, ACHL, and ASRT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2025LPTXLeap TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/19/2025ASRTAssertioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$4.00 ➝ $3.503/14/2025ASRTAssertioIndustrial Alliance SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$1.75(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACHLAchilles TherapeuticsN/AN/AN/AN/A$3.49 per shareN/AASRTAssertio$124.96M0.47$0.54 per share1.12$1.46 per share0.42LPTXLeap TherapeuticsN/AN/AN/AN/A$2.35 per shareN/APYRGFPyroGenesis Canada$9.14M6.74N/AN/A($0.01) per share-33.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACHLAchilles Therapeutics-$69.67M-$1.65N/AN/AN/AN/A-54.45%-47.68%N/AASRTAssertio-$331.94M-$0.32N/A20.293.25-54.46%3.79%1.81%N/ALPTXLeap Therapeutics-$81.41M-$1.84N/AN/AN/AN/A-116.24%-93.18%N/APYRGFPyroGenesis Canada-$21.12M-$0.02N/A∞N/A-115.14%N/A-60.81%N/ALatest LPTX, PYRGF, ACHL, and ASRT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025ASRTAssertio-$0.06-$0.14-$0.08-$0.14$27.52 million$26.49 million3/26/2025Q4 2024LPTXLeap Therapeutics-$0.39-$0.37+$0.02-$0.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACHLAchilles TherapeuticsN/AN/AN/AN/AN/AASRTAssertioN/AN/AN/AN/AN/ALPTXLeap TherapeuticsN/AN/AN/AN/AN/APYRGFPyroGenesis CanadaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACHLAchilles TherapeuticsN/A6.046.04ASRTAssertio0.302.011.57LPTXLeap TherapeuticsN/A3.973.97PYRGFPyroGenesis CanadaN/A0.600.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACHLAchilles Therapeutics56.38%ASRTAssertio48.96%LPTXLeap Therapeutics30.46%PYRGFPyroGenesis Canada0.03%Insider OwnershipCompanyInsider OwnershipACHLAchilles Therapeutics5.38%ASRTAssertio4.00%LPTXLeap Therapeutics5.40%PYRGFPyroGenesis Canada47.68%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACHLAchilles Therapeutics25041.10 million38.89 millionNot OptionableASRTAssertio2095.77 million92.42 millionOptionableLPTXLeap Therapeutics4041.44 million36.25 millionOptionablePYRGFPyroGenesis Canada90186.69 million96.34 millionNo DataLPTX, PYRGF, ACHL, and ASRT HeadlinesRecent News About These CompaniesPyroGenesis Announces First Quarter 2025 ResultsMay 13 at 9:30 PM | globenewswire.comPyroGenesis Provides Update on Fumed Silica ProjectMay 13 at 7:00 AM | globenewswire.comPyroGenesis Closes $2,385,000 First Tranche in Previously Announced LoanMay 12 at 7:30 AM | globenewswire.comPyroGenesis Canada (NASDAQ:PYRGF) Trading Down 0.2% - Should You Sell?May 11 at 6:04 AM | marketbeat.comPyroGenesis Schedules First Quarter 2025 Financial Results and Business Update Conference CallMay 9, 2025 | globenewswire.comPyroGenesis Announces Closing of Non-Brokered Private Placement of up to $5,750,000May 5, 2025 | globenewswire.comPyroGenesis Canada (NASDAQ:PYRGF) Trading Up 1.4% - Still a Buy?April 19, 2025 | marketbeat.comP. Peter Pascali Updates Early Warning ReportApril 10, 2025 | globenewswire.comPyroGenesis Inc. (PYRGF) Q4 2024 Earnings Call TranscriptApril 1, 2025 | seekingalpha.comPyroGenesis Announces Fourth Quarter and Full Year 2024 ResultsMarch 31, 2025 | globenewswire.comPyroGenesis Schedules 2024 Fiscal Year Financial Results and Business Update Conference CallMarch 26, 2025 | globenewswire.comPyroGenesis Inc.: PyroGenesis Provides Update on Varennes Carbon Recycling ProjectMarch 21, 2025 | finanznachrichten.dePyroGenesis Provides Update on Varennes Carbon Recycling ProjectMarch 21, 2025 | globenewswire.comHPQ’s Statement on U.S. - Canada Tariff Situation, Reinforces Case for Domestic Fumed Silica ProductionMarch 12, 2025 | markets.businessinsider.comPyroGenesis and GE Vernova Sign Memorandum of Understanding (MOU)March 11, 2025 | globenewswire.comPyroGenesis Provides Response to Impact of U.S. TariffsMarch 4, 2025 | globenewswire.comPyroGenesis in final stages of Boeing supplier qualification for course titanium powderMarch 4, 2025 | pm-review.comPyroGenesis Improves Key Performance Parameters of its NexGenTM Plasma Atomized Metal Powder Production SystemMarch 4, 2025 | markets.businessinsider.comTechnical Requirements for Titanium Coarse Metal Powder Have Been Met by PyroGenesis' NexGen™ Plasma Atomized Metal Powder for Global Aerospace OEMMarch 3, 2025 | globenewswire.comPyroGenesis Announces First Material Produced from Fumed Silica ReactorFebruary 27, 2025 | globenewswire.comPyroGenesis signs plasma torch contract with Norsk HydroFebruary 24, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLPTX, PYRGF, ACHL, and ASRT Company DescriptionsAchilles Therapeutics NASDAQ:ACHL$1.48 0.00 (0.00%) As of 03/26/2025Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.Assertio NASDAQ:ASRT$0.61 -0.01 (-1.09%) As of 05/13/2025 04:00 PM EasternAssertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.Leap Therapeutics NASDAQ:LPTX$0.40 +0.02 (+6.64%) As of 05/13/2025 04:00 PM EasternLeap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.PyroGenesis Canada NASDAQ:PYRGF$0.33 0.00 (-0.36%) As of 05/13/2025 11:38 AM EasternPyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Stock Surges on Bullish News: How High Could It Climb? NuScale Power in Rebound Mode With Short-Squeeze a Possibility Why Amazon May Never Dip Below $200 Again eBay Nears Big Breakout: Time to Buy the Under-the-Radar Winner? Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long Why Boeing May Be Ready to Take Off After Latest Developments Goldman Sachs Warns of 20% Market Sell-Off: Are They Right? 3 Huge S&P 500 Winners From Trump Trade Deal & The Biggest Loser Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
